Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVIR NASDAQ:ENGN NASDAQ:INKT NASDAQ:MNPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$3.14-4.8%$3.52$2.45▼$4.14$249.18M0.25250,537 shs182,103 shsENGNenGene$5.71-5.8%$4.12$2.65▼$11.00$291.81M-0.4216,061 shs86,055 shsINKTMiNK Therapeutics$14.40-1.7%$16.88$4.56▼$76.00$65.13M0.3346,921 shs37,016 shsMNPRMonopar Therapeutics$49.22+3.3%$39.33$3.33▼$54.30$303.68M1.238,061 shs22,352 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals0.00%-6.82%-10.03%-0.63%-14.44%ENGNenGene0.00%+10.23%+58.17%+71.47%-14.78%INKTMiNK Therapeutics0.00%-2.70%-6.01%+96.99%+85.81%MNPRMonopar Therapeutics0.00%+11.33%+37.26%+46.84%+1,950.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$3.14-4.8%$3.52$2.45▼$4.14$249.18M0.25250,537 shs182,103 shsENGNenGene$5.71-5.8%$4.12$2.65▼$11.00$291.81M-0.4216,061 shs86,055 shsINKTMiNK Therapeutics$14.40-1.7%$16.88$4.56▼$76.00$65.13M0.3346,921 shs37,016 shsMNPRMonopar Therapeutics$49.22+3.3%$39.33$3.33▼$54.30$303.68M1.238,061 shs22,352 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals0.00%-6.82%-10.03%-0.63%-14.44%ENGNenGene0.00%+10.23%+58.17%+71.47%-14.78%INKTMiNK Therapeutics0.00%-2.70%-6.01%+96.99%+85.81%MNPRMonopar Therapeutics0.00%+11.33%+37.26%+46.84%+1,950.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVIRAtea Pharmaceuticals 2.50Moderate Buy$6.0091.08% UpsideENGNenGene 3.00Buy$21.00267.78% UpsideINKTMiNK Therapeutics 2.60Moderate Buy$37.50160.42% UpsideMNPRMonopar Therapeutics 3.00Buy$71.7545.77% UpsideCurrent Analyst Ratings BreakdownLatest INKT, MNPR, AVIR, and ENGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025ENGNenGeneMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$19.00 ➝ $18.009/9/2025MNPRMonopar TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$87.009/8/2025ENGNenGeneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.009/3/2025MNPRMonopar TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$77.009/2/2025MNPRMonopar TherapeuticsRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$80.008/27/2025MNPRMonopar TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$74.008/26/2025MNPRMonopar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$70.008/18/2025INKTMiNK TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell8/15/2025INKTMiNK TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$35.00 ➝ $35.008/13/2025MNPRMonopar TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.007/18/2025INKTMiNK TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVIRAtea PharmaceuticalsN/AN/AN/AN/A$5.20 per shareN/AENGNenGeneN/AN/AN/AN/A$5.35 per shareN/AINKTMiNK TherapeuticsN/AN/AN/AN/A($4.94) per shareN/AMNPRMonopar TherapeuticsN/AN/AN/AN/A$9.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVIRAtea Pharmaceuticals-$168.38M-$1.61N/AN/AN/AN/A-32.55%-30.47%11/6/2025 (Estimated)ENGNenGene-$55.14M-$1.900.00N/AN/AN/A-39.86%-34.15%N/AINKTMiNK Therapeutics-$9.51M-$2.88N/AN/AN/AN/AN/A-227.24%11/13/2025 (Estimated)MNPRMonopar Therapeutics-$15.59M-$3.33N/AN/AN/AN/A-41.76%-39.49%11/14/2025 (Estimated)Latest INKT, MNPR, AVIR, and ENGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/11/2025Q3 2025ENGNenGene-$0.5084-$0.57-$0.0616-$0.57N/AN/A8/14/2025Q2 2025INKTMiNK Therapeutics-$0.55-$1.06-$0.51-$1.06N/AN/A8/12/2025Q2 2025MNPRMonopar Therapeutics-$0.47-$0.35+$0.12-$0.35N/AN/A8/7/2025Q2 2025AVIRAtea Pharmaceuticals-$0.46-$0.44+$0.02-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/AENGNenGeneN/AN/AN/AN/AN/AINKTMiNK TherapeuticsN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVIRAtea PharmaceuticalsN/A19.1719.17ENGNenGene0.0910.3410.34INKTMiNK TherapeuticsN/A0.150.15MNPRMonopar TherapeuticsN/A33.9333.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVIRAtea Pharmaceuticals86.67%ENGNenGene64.16%INKTMiNK Therapeutics2.87%MNPRMonopar Therapeutics1.83%Insider OwnershipCompanyInsider OwnershipAVIRAtea Pharmaceuticals18.10%ENGNenGene10.40%INKTMiNK Therapeutics22.48%MNPRMonopar Therapeutics20.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVIRAtea Pharmaceuticals7079.36 million64.99 millionOptionableENGNenGene3151.10 million45.79 millionN/AINKTMiNK Therapeutics304.52 million3.51 millionNo DataMNPRMonopar Therapeutics106.17 million4.91 millionNot OptionableINKT, MNPR, AVIR, and ENGN HeadlinesRecent News About These CompaniesMonopar to Present New Long-Term Neurological Efficacy and Safety Data for ALXN1840 in Wilson Disease at the 150th American Neurological Association Annual MeetingSeptember 14 at 8:00 AM | globenewswire.comBTIG Research Begins Coverage on Monopar Therapeutics (NASDAQ:MNPR)September 11 at 8:13 AM | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Coverage Initiated by Analysts at BTIG ResearchSeptember 10, 2025 | americanbankingnews.comMonopar Therapeutics initiated with a Buy at BTIGSeptember 9, 2025 | msn.comBTIG Initiates Coverage of Monopar Therapeutics (MNPR) with Buy RecommendationSeptember 9, 2025 | msn.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Receives $69.57 Average Target Price from AnalystsSeptember 9, 2025 | americanbankingnews.comMonopar Therapeutics Inc. (NASDAQ:MNPR) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 8, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Takes Position in Monopar Therapeutics Inc. $MNPRSeptember 6, 2025 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Coverage Initiated at OppenheimerSeptember 5, 2025 | marketbeat.comOppenheimer Initiates Coverage of Monopar Therapeutics (MNPR) with Outperform RecommendationSeptember 4, 2025 | msn.comADAR1 Capital Management LLC Has $3.67 Million Holdings in Monopar Therapeutics Inc. $MNPRSeptember 4, 2025 | marketbeat.comRaymond James Initiates Coverage of Monopar Therapeutics (MNPR) with Strong Buy RecommendationSeptember 4, 2025 | msn.comOppenheimer starts Monopar with Outperform on ALXN1840 potentialSeptember 3, 2025 | msn.comMonopar Therapeutics initiated with an Outperform at OppenheimerSeptember 3, 2025 | msn.comMonopar Announces Abstract Accepted with Distinction for Oral and Poster Presentations at the Upcoming American Neurological Association 2025 Annual MeetingSeptember 3, 2025 | globenewswire.comMonopar Therapeutics initiated with a Strong Buy at Raymond JamesSeptember 2, 2025 | msn.comQ3 Earnings Estimate for MNPR Issued By HC WainwrightAugust 30, 2025 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Given Overweight Rating at Cantor FitzgeraldAugust 29, 2025 | marketbeat.comAffinity Asset Advisors LLC Buys Shares of 62,000 Monopar Therapeutics Inc. $MNPRAugust 28, 2025 | marketbeat.comMonopar Therapeutics (NASDAQ:MNPR) Given Buy Rating at HC WainwrightAugust 28, 2025 | marketbeat.comMonopar Therapeutics assumed with a Buy at H.C. WainwrightAugust 26, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINKT, MNPR, AVIR, and ENGN Company DescriptionsAtea Pharmaceuticals NASDAQ:AVIR$3.14 -0.16 (-4.85%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.20 +0.06 (+2.04%) As of 09/12/2025 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.enGene NASDAQ:ENGN$5.71 -0.35 (-5.78%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$5.72 +0.01 (+0.26%) As of 09/12/2025 05:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.MiNK Therapeutics NASDAQ:INKT$14.40 -0.25 (-1.71%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$14.30 -0.10 (-0.69%) As of 09/12/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.Monopar Therapeutics NASDAQ:MNPR$49.22 +1.55 (+3.25%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$49.38 +0.16 (+0.33%) As of 09/12/2025 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
